Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.7 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.
Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 260 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Domain Russia Investments (DRI) is a company formed by U.S.-based life sciences venture capital firm Domain Associates to help foster innovation in the Russian health sciences sector. DRI plays a crucial role in Domain’s unique strategic collaboration with Rusnano. The collaboration focuses on co-investment into leading US life sciences companies and the eventual production of their in
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
26 April 2017
25 April 2017